(Press-News.org) The addition of the cancer immunotherapy drug atezolizumab to the standard of care concurrent chemoradiation (cCRT) did not improve overall survival for patients with limited-stage small cell lung cancer (LS-SCLC) in the second planned interim analysis of the NRG Oncology/Alliance NRG-LU005 clinical trial. These results were recently reported during the Plenary Session of the American Society for Radiation Oncology Annual Meeting in Washington, DC.
“While atezolizumab given concurrently with chemoradiation did not improve survival, we have still learned quite a bit from these findings. With the success of the ADRIATIC trial presented at ASCO earlier this year, it is clear that LS-SCLC patients benefit from immunotherapy, but it should be given after completion of chemoradiation and not concurrently. Our results also suggest that twice daily radiation may have performed better and could be considered the preferred radiation regimen for these patients,” stated Kristin A. Higgins, MD, Professor of Radiation Oncology at City of Hope National Medical Center and Chief Clinical Officer, City of Hope Atlanta, and the lead author of the NRG-LU005 abstract.
NRG-LU005 is an open-label, randomized, phase III, international clinical study that enrolled 554 eligible patients with LS-SCLC in the U.S. and Japan. Patients received one cycle of chemotherapy prior to registration onto the trial. Following registration, patients were stratified by choice of cisplatin or carboplatin chemotherapy, their radiation fractionation schedule, sex, and ECOG performance status and then were randomly assigned to receive either cCRT alone or cCRT with atezolizumab at 1200 mg every three weeks for a maximum of 17 cycles. The primary aim of NRG-LU005 was to compare overall survival with and without atezolizumab.
At the second planned interim analysis at a median follow up of 21 months for all patients, the 1, 2, and 3 year overall survival rates were 82.6% (95% CI 77.2 - 86.9), 62.9% (95% CI 56.2 - 69.0) and 50.3% (95% CI 42.3 - 57.8) for control, and 80.2% (95% CI 74.7 - 84.6), 58.6% (95% CI 52.1- 64.6) and 44.7% (95% CI 36.6 - 52.4) for adding atezolizumab, respectively. The median overall survival for cCRT alone was 39.5 months (95% CI 27.5 - Not reached) and 33.1 months for the atezolizumab arm (HR= 1.11, 95% CI: 0.85-1.45). No new or unexpected safety findings were noted.
In addition to the primary objectives, NRG-LU005 also included secondary objectives comparing the following rates between treatments: progression-free survival, distant metastasis-free survival, cumulative incidence of local failure, complete or partial response, and adverse events.
This study was sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, was supported by grants U10CA180868 (NRG Oncology Operations), U10CA180822 (NRG Oncology SDMC), UG1CA189867 (NCORP), U24CA196067 (NRG Specimen Bank), U24CA180803 (IROC) from the NCI and Genentech by Genentech, a member of the Roche Group under a Cooperative Research and Development Agreement between NCI and Genentech.
Special Podcast Episode
Follow The NRG Oncology Podcast on Spotify, Apple Podcasts, and YouTube for a special episode interviewing Drs. Kristin Higgins and Sue Yom on the findings of the 2024 ASTRO Plenary Session Presentations for NRG-LU005 and NRG-HN005. Podcast information is available on the NRG website as well.
Citation
Higgins KA, Hu C, Ross HJ, Jabbour SK, Kozono DE, Owonikoko TK, Kaira K, Gupta AK, Mohindra P, Dib EG, Brownstein J, Chun S, Kuzma CS, Kotecha RR, Onitilo AA, Chen Y, Stinchcombe TE, Wang XF, Paulus R, Bradley JD. (2024, September-October). Concurrent Chemoradiation +/- Atezolizumab in limited-stage small cell lung cancer (LS-SCLC): Results of NRG Oncology/Alliance LU005. Paper presented during the Plenary Session at the annual meeting of the American Society for Radiation Oncology. Washington, DC.
About NRG Oncology
NRG Oncology conducts practice-changing, multi-institutional clinical and translational research to improve the lives of patients with cancer. Founded in 2012, NRG Oncology is a Pennsylvania-based nonprofit corporation that integrates the research of the legacy National Surgical Adjuvant Breast and Bowel Project (NSABP), Radiation Therapy Oncology Group (RTOG), and Gynecologic Oncology Group (GOG) programs. The research network seeks to carry out clinical trials with emphases on gender-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types. NRG Oncology’s extensive research organization comprises multidisciplinary investigators, including medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians, and encompasses more than 1,300 research sites located world-wide with predominance in the United States and Canada. NRG Oncology is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI’s National Clinical Trials Network.
www.nrgoncology.org
Atezolizumab (Tecentriq®) is a registered trademark of Genentech, a member of the Roche Group.
END
NRG Oncology trial implies the addition of atezolizumab concurrently to standard of care does not improve survival in limited-stage small cell lung cancer
2024-09-30
ELSE PRESS RELEASES FROM THIS DATE:
NRG Oncology trial supports radiotherapy and cisplatin should remain the standard of care for p16+ oropharyngeal cancer
2024-09-30
The NRG Oncology NRG-HN005 phase II/III clinical trial did not meet the non-inferiority criteria to proceed to the phase III portion of the study. The phase II portion of the NRG-HN005 evaluated two experimental treatment arms against a control arm for patients with p16-positive (p16+, accepted as a surrogate for HPV+ status), locoregionally advanced oropharyngeal cancer. The interim futility results were recently reported during the Plenary Session of the American Society for Radiation Oncology Annual Meeting in Washington, DC.
“This ...
Progression of subclinical atherosclerosis predicts all-cause mortality risk
2024-09-30
A study carried out at Mount Sinaí Fuster Heart Hospital in New York in collaboration with the Centro Nacional de Investigaciones Cardiovasculares (CNIC) in Madrid provides important new information about atherosclerosis, a disease in which lipids (cholesterol) and other substances accumulate in plaques on the arterial wall, causing the vessels to harden and narrow, and increasing the risk of severe cardiovascular conditions.
The study, published in The Journal of the American College of Cardiology (JACC), was led by Dr. Valentín Fuster, Director of the Cardiovascular ...
Presence of subclinical atherosclerosis is marker of mortality and its progression increases risk of death
2024-09-30
The progression of atherosclerosis in people who have no symptoms of it is independently associated with the risk of dying from any cause, according to a new study led by researchers from Mount Sinai Fuster Heart Hospital, published September 30 in the Journal of the American College of Cardiology.
This research is also the first to show that advanced imaging can detect atherosclerotic disease of the large vessels long before the appearance of symptoms—an approach that could be used worldwide to prevent cardiovascular disease and risk of death. Together, the findings ...
Wang unlocking complex heterogeneity in large spatial-temporal data with scalable quantile learning
2024-09-30
Lily Wang, Professor, Statistics, College of Engineering and Computing (CEC), received funding for the project: “Collaborative Research: Unlocking Complex Heterogeneity in Large Spatial-Temporal Data with Scalable Quantile Learning.”
Wang and her collaborator, Huixia Judy Wang, Department Chair and Professor of Statistics at The George Washington University, are developing scalable and efficient quantile learning techniques and theories to address challenges in analyzing large-scale heterogeneous spatial and temporal data. These new analytical techniques will have wide-ranging applications, revolutionizing scientists’ understanding of spatial and temporal ...
Heart transplant patients from socioeconomically deprived areas face higher risk for postoperative complications, earlier death than others
2024-09-30
Heart transplant patients who live in socioeconomically disadvantaged areas are more likely to experience post-surgical complications and die within five years than patients who live in more advantaged areas, even when those patients were transplanted at topnotch high-volume hospitals, new UCLA research suggests.
The findings, to be published September 30 in the peer-reviewed Journal of Heart and Lung Transplantation, the official publication of the International Society for Heart and Lung Transplantation, suggest that a lack of access ...
Research alert: skin barrier protein also protects against inflammation
2024-09-30
Researchers at University of California San Diego School of Medicine have identified a new mechanism underlying inflammatory skin diseases, such as psoriasis and seborrheic dermatitis. They found that a protein essential in forming the skin’s protective barrier (ZNF750) also plays a role in controlling inflammation in skin cells, shedding light on why some people are more susceptible to inflammatory skin diseases than others. The study paves the way for more effective and personalized therapies for these debilitating diseases and also offers broader ...
Saint Luke’s and UMKC to lead nationwide study on pregnant people with heart disease in effort to help combat maternal morbidity, mortality
2024-09-30
KANSAS CITY, Mo. (September 30, 2024) – The University of Missouri-Kansas City Healthcare Institute for Innovations in Quality and Saint Luke’s Mid America Heart Institute today announced a nationwide, four-year observational study of U.S. pregnant people with cardiovascular disease to better understand and combat maternal mortality and morbidity.
The National Heart, Lung, and Blood Institute of the National Institutes of Health awarded more than $7.9 million to the UMKC Healthcare Institute for Innovations in Quality to fund the study, Heart Outcomes in Pregnancy Expectations (HOPE) ...
Spiritual themes, distrust may factor into Black patients’ reluctance to participate in cancer clinical trials
2024-09-30
WASHINGTON, September 30, 2024 — Spiritual beliefs and a historically-based distrust of clinical research may factor into Black patients’ decisions about whether to participate in cancer trials, according to surveys of patients treated at two Baltimore medical centers. Findings will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
This cross-sectional, descriptive study found lingering distrust in clinical research among Black patients, despite their self-reported trust in their cancer medical teams. The surveys sought to shed light on what might be contributing to the growing underrepresentation of Black people in cancer trials ...
Brigham study finds older adults who experience a fall are at increased risk of dementia
2024-09-30
In a retrospective study of Medicare claims data, researchers found dementia was more frequently diagnosed within one year of a fall compared to other types of injuries.
KEY TAKEAWAYS
In a retrospective cohort study involving more than 2 million older adults who sustained an injury, 10.6% of patients who experienced a fall were subsequently diagnosed with dementia.
Compared to other types of injuries, falls were associated with a 21% increased risk for future dementia diagnosis.
Findings support implementing cognitive screenings for older adults who have experienced a fall resulting in an emergency room visit or hospital admission.
Researchers ...
Trends in female physicians entering high-compensation specialties
2024-09-30
About The Study: This study found that female physicians were underrepresented among residents entering high-compensation specialties compared with non–high-compensation specialties. However, while high-compensation surgical specialties experienced a steady increase in the proportion of female applicants and matriculants over time, high-compensation nonsurgical specialties experienced an overall decrease in the proportion of female applicants and no significant changes in the proportion of female matriculants.
Corresponding Author: To contact the corresponding author, Karina Pereira-Lima, PhD, ...